With the appropriate use of preadmission clinics, "hospital in the home" programs, and alternatives to intravenous heparin, the majority of chronically anticoagulated patients can be managed as outpatients prior to elective surgery. The preoperative management depends on the original indication for long-term anticoagulation, the interval since the last thromboembolic event, and the extent and type of surgery planned. Only patients who are undergoing major surgery, and who have a high risk of recurrent thrombosis or embolism, require preoperative admission to hospital and conversion to an intravenous heparin regimen. Patients undergoing minor surgery may require no change to their oral anticoagulation. The remainder require cessation of oral anticoagulation and alternative thromboprophylaxis preoperatively, which can be achieved on an outpatient basis using low molecular weight heparin. Outpatient anticoagulation management requires a clear protocol that is understood and agreed to by all parties involved in the care of surgical patients perioperatively.
The practice of admitting patients to hospital for several days prior to elective surgery has largely been eliminated. The introduction of multi-disciplinary Pre-Admission Clinics (PACs) has made it possible for preoperative anaesthetic assessment, patient education, informed consent and preoperative preparation for most forms of surgery to be performed on an outpatient basis. In this way the patient is able to present fully prepared on the day of surgery.
One patient group that has remained difficult to manage on an outpatient basis prior to elective surgery is the group receiving chronic anticoagulant therapy. For many years standard management for these patients has involved hospital admission some three to four days before surgery, cessation of warfarin therapy, and conversion to a titratable intravenous (IV) heparin regimen. Inpatient management prior to elective surgery may no longer be necessary for the majority of these patients. The introduction of effective alternatives to IV heparin, coupled with the availability of PACs and "hospital in the home" programs, makes preoperative outpatient management a realistic option for the majority of anticoagulated patients. Improved understanding of thromboembolic diseases has further reduced the need for preoperative inpatient management. In this paper the current evidence about thromboembolic risk factors is summarized, and the use of low molecular weight heparin for preoperative thromboprophylaxis is discussed. Using this information, guidelines are submitted for the categorization of risk, and the preoperative outpatient management of chronically anticoagulated patients prior to elective surgery.
CATEGORIZATION OF THROMBOEMBOLIC RISK
Indications for chronic anticoagulant therapy cover a heterogeneous group of disorders that have different pathophysiologies, severities, and risks. Patients who have both a high risk of recurrent thromboembolism if anticoagulation is ceased and a high risk of surgical bleeding if anticoagulation is continued, may require admission to hospital and an individualized anticoagulation regimen. These are the minority of patients. The remainder can either continue their anticoagulation perioperatively (if they have a low risk of surgical bleeding), cease their anticoagulation temporarily (if they have a low risk of thrombosis or embolism), or convert to a subcutaneous heparin regimen, with dosage adjusted for risk. None of these latter options requires admission to hospital preoperatively. The challenge is determining the correct category to place individual patients. This requires an understanding of the indications for chronic anticoagulation, the risks of recurrent thromboembolism if anticoagulation is ceased, and the risks of bleeding if anticoagulation is continued.
The two most common indications for chronic anticoagulation for arterial thromboembolism are atrial fibrillation and the presence of a mechanical heart valve. In addition, certain patients with carotid stenosis or peripheral vascular disease receive longterm oral anticoagulation. For venous thromboembolism, the most common indication is a history of venous thromboembolism, with or without a familial prothrombotic state. In practice, a familial prothrombotic state is rarely diagnosed without a history of previous thrombosis.
Atrial Fibrillation
Atrial fibrillation (AF) is associated with an increased risk of arterial thromboembolism. The overall annual risk of embolic stroke in untreated patients is 4.5%, although this ranges from 1.0% to 8.5% in non-valvular AF, depending on the presence or absence of associated risk factors [1] [2] [3] . Co-existing valve dysfunction places the patient at higher risk (up to 17 times the control rate) 4 . Ventricular dysfunction, left atrial enlargement, ischaemic heart disease and advanced age also put the patient at increased risk for thromboembolism [1] [2] [3] [4] . The risk of recurrence appears to be greatest within the first month after a thromboembolic event. Patients with AF can accordingly be divided into three distinct risk groups: Low Risk* All other patients with AF *Note that AF patients have a higher incidence of arterial thromboembolism than equivalent patients without AF, even if they are categorized as low risk.
High risk factors

Mechanical Heart Valves
The average rate of arterial thromboembolism after placement of a mechanical heart valve without thromboprophylaxis is in the region of 8% per annum 5 . This can be reduced to less than 2% with appropriate anticoagulation 5 . A spectrum of risk exists among patients with mechanical valves depending upon the type of valve, the interval since replacement, the position of the valve and patient comorbidities 5 . Factors increasing the risk include co-existing atrial fibrillation, previous history of thromboembolism, advanced age and mitral position [5] [6] [7] . Poor ventricular function and pregnancy are also associated with a higher risk. Caged-ball valves are associated with a higher incidence of thromboembolism than either bi-leaflet, or tilting disc valves [5] [6] [7] . The period of greatest risk appears to be the first 90 days after replacement, even for bioprostheses 5 . 
High risk factors
Low risk
There are no mechanical heart valves that can be considered "low risk" for thromboembolism if anticoagulation is ceased.
Carotid Stenosis
Extracranial carotid disease accounts for about 50% of all strokes [8] [9] [10] . Asymptomatic stenosis or bruit (1.5-2% stroke rate per year), and previous transient ischaemic attack (6% stroke rate per year) are pre-dictors for future stroke. Aspirin is the agent of choice in most cases where long-term arterial thromboembolism prophylaxis is required in patients with vascular disease. The reported frequency of use of oral anticoagulants in this population, as an alternative or in addition to aspirin, is about 35%. Most practitioners favour reserving oral anticoagulants for patients with a higher degrees of stenosis or with recent symptoms 11 . The risk-benefit ratio of warfarin prophylaxis as opposed to aspirin remains controversial. As such, all patients with this indication could be considered at low risk of arterial thromboembolism if warfarin is temporarily ceased. Continuation of aspirin therapy for patients with carotid stenosis is recommended [10] [11] [12] . Elective surgery should be avoided in patients with recent symptoms (<30 days). Similar considerations apply to patients who are receiving oral anticoagulation for peripheral vascular disease.
Deep Venous Thrombosis and Thromboembolism
Discontinuation of anticoagulation within one month of an acute deep venous thrombosis (DVT) or pulmonary embolism (PE) is associated with a risk of recurrence of about 40% per annum. The risk reduces to 10 to 15% per annum one to three months after the acute event 13 . Thereafter, the risk stabilizes at about 5% per annum. Major surgery substantially increases the risk for recurrence of venous thrombosis or embolism, independent of other risk factors [14] [15] [16] . Patients with coexisting obesity, malignant disease, familial prothrombotic state or preoperative immobility are at highest risk. Elective surgery should be postponed in all patients with venous thrombosis until they have received a minimum of three months of anticoagulation. Surgery should be avoided if at all possible within one month of a thromboembolic event. 
High risk factors
CATEGORIZATION OF BLEEDING RISK
Preoperative management of the chronically anticoagulated patient is influenced also by the nature of the planned surgery. The main surgical concern is abnormal bleeding if anticoagulation is continued or incompletely reversed. Increased intraoperative blood loss, haemodynamic instability, wound haematoma, and subsequent infection are all potential complications, depending on the extent and site of surgery.
High risk
Major procedures involving the airway, joints, the head and neck, or body cavities, carry a risk of clinically significant bleeding if oral anticoagulation is continued. These patients require cessation of oral anticoagulation preoperatively. The need for alternative thromboprophylaxis preoperatively will depend on the risk of recurrent thromboembolism if anticoagulation is ceased. Many surgical procedures, although not major, are associated with high morbidity if abnormal surgical bleeding occurs. These include, but are not limited to, certain neurosurgical, orthopaedic, plastic, and ophthalmological procedures. In these patients, normal coagulation is required during surgery and in the immediate postoperative period. This can be achieved only if oral anticoagulation is ceased several days preoperatively, and no heparin effect is present at the time of surgery.
Low risk
Minor procedures on the skin or subcutaneous tissues have a low risk of abnormal surgical bleeding. Oral anticoagulation can be continued perioperatively for these patients.
THROMBOPROPHYLAXIS WITH LOW MOLECULAR WEIGHT HEPARIN
Low molecular weight heparins (LMWHs) are the preferred choice for outpatient management because they have pharmacokinetic and pharmacodynamic advantages when compared to unfractionated heparin (UH) or warfarin [17] [18] [19] . Their serum levels are predictable after subcutaneous administration and correlate closely with anti-Xa activity. Unlike UHs, they have low plasma protein binding and are not taken up by the reticuloendothelial system. For these reasons LMWH therapy has a better safety profile than UH, and does not require routine laboratory monitoring [17] [18] [19] . Before advocating the use of LMWH in an outpatient-based, perioperative anticoagulation service, a number of issues concerning LMWH must be addressed:
Does LMWH provide as effective thromboprophylaxis as UH?
The introduction of LMWHs has allowed for community-based management of a range of clinical disorders that previously required inpatient IV heparin therapy. Several studies have confirmed the efficacy of LMWHs across a range of conditions where anticoagulation or thrombosis prophylaxis is indicated. Dose-adjusted treatment of deep venous thrombosis and pulmonary embolism with LMWH outside the hospital has been shown to produce predictable and effective levels of anticoagulant activity, to require less monitoring, and to be more cost-effective than treatment with unfractionated heparin [20] [21] [22] [23] [24] [25] . Long-term self-administration of LMWH has been shown to be both feasible and safe in patients with contraindications to warfarin 26 . Successful outpatient management of arterial thromboembolic disease with LMWH has also been reported [27] [28] [29] .
In addition, LMWHs are being used as an alternative to UH in the treatment of unstable angina and non-Q-wave infarction 30, 31 . Within hospital, LMWHs have been used as alternative agents where full anticoagulation is required. They have been shown to have at least a similar efficacy and safety as UH in haemodialysis, with the additional advantages of a simplified administration regimen, and a lower incidence of heparin-induced thrombocytopenia 32 . Successful postoperative anticoagulation with LMWHs following mechanical valve replacement has been reported 33 .
These findings suggest that LMWHs are as effective as unfractionated heparin, both therapeutically and prophylactically, and can be used safely in the community. They would appear to be the preferred agents for antithrombotic prophylaxis for patients who require interruption of their oral anticoagulation perioperatively.
Which low molecular weight heparin and which dose?
The bioequivalence of individual LMWHs varies depending on their plasma half-life and ratio of anti-Xa/IIa activity 34 . Enoxaparin (Clexane, Aventis Pharma, Lane Cove, N.S.W.) and dalteparin (Fragmin, Pharmacia, NJ, U.S.A.) are the two most commonly used LMWHs in Australasia. The oncedaily dosage of enoxaparin is more suited to the outpatient setting and is the preferred agent at our institution. At low doses (20 to 40 mg/day) it has effective anti-thrombotic properties but is an ineffective anticoagulant. For deep venous thrombosis prevention the manufacturer quotes a "low dose" prophylaxis of 20 mg/day, and a "high dose" prophylaxis of 40 mg/day. At higher doses, (1.0 to 1.5 mg/kg/day) it is an effective anticoagulant, and is an alternative to therapeutic doses of unfractionated heparin IV.
Safety and reversibility of LMWH in surgical patients
The inability to completely reverse the effects of LMWH with protamine makes LMWH potentially less safe than UH. Only 60% of the antithrombotic activity (anti-Xa activity) of LMWH can be reversed with protamine (1 mg per mg enoxaparin) 19 . However, if there is an appropriate interval between the last dose of enoxaparin and the commencement of surgery, the risks of abnormal bleeding are minimal. This issue was discussed at a consensus conference convened by the American Society of Regional Anesthesia in 1998 35 . An interval of 10 to 12 h following prophylactic doses (up to 40 mg enoxaparin per day) was recommended and at least 24 h following therapeutic doses (1 mg/kg of enoxaparin per day) 36 . These recommendations were based on the known pharmacokinetics of LMWHs. The consensus conference also recommended that preoperative monitoring of anti-Xa activity was not necessary 36 .
GUIDELINES FOR PREOPERATIVE MANAGEMENT
These guidelines are based on the authors' interpretation of the current evidence and practice, but not formal outcome data or a meta-analysis. They are based largely on previous recommendations and risk calculations, which have been modified to cover management in the outpatient setting. They have been formulated to provide a conservative approach to both the categorization of risk and the safe management of chronically anticoagulated patients preoperatively. Kearon and Hirsh in their review indicated that not all chronically anticoagulated patients have the same risk of perioperative thromboembolic events 13 . They sought to balance the relative risks of thromboembolism and abnormal bleeding, and advocated preoperative therapeutic anticoagulation only for those patients who had sustained an acute thromboembolic event within the previous 30 days 13 . Their paper attracted considerable comment. Some writers expressed concerns that including all other AF patients and all other mechanical heart valve patients in the "low-risk group" (no alternative anticoagulation required) oversimplified the problem [37] [38] [39] . The authors have incorporated these concerns, and have modified Kearon and Hirsh's recommendations accordingly.
Management of oral anticoagulation
If the surgical team is agreeable, patients with a low risk of surgical bleeding (see above) can continue their oral anticoagulation perioperatively [40] [41] [42] [43] . All remaining patients should cease their warfarin at least five days preoperatively 13 . This will allow the international normalized prothrombin ratio (INR) to fall to 1.5 or less by the day of surgery in the majority of cases 13, 44 . The INR is the current international standard for monitoring and reporting warfarin effect 45 . Most surgical procedures are avoided if the INR is >1.4 44, 45 . Alternative thromboprophylaxis should be commenced four days preoperatively. The form of thromboprophylaxis will depend on the patient's thromboembolic risk category.
Recent thromboembolic event (<30 days, or residual thrombus present)
Defer surgery if possible. If deferral is not possible, cease warfarin five days preoperatively. Admit to hospital four days preoperatively and commence therapeutic anticoagulation with IV heparin. (If IV heparin is contraindicated in patients with recent venous thromboembolism, consider insertion of an inferior vena caval filter preoperatively.)
No Thromboembolic Event Within 30 Days But Other High Risk Factors Present
For elective patients defer surgery if deferral is associated with reduced risk of thromboembolism (e.g., thromboembolic event or valve replacement within one to three months). If deferral is not possible (or does not reduce risk), cease warfarin five days preoperatively. Commence enoxaparin 1.0 to 1.5 mg/day (depending on the number of risk factors) four days preoperatively. This can be performed as an outpatient. Ensure that there is a minimum 24 h interval between the last enoxaparin dose and the commencement of surgery. Measure the INR on the day before surgery. If the INR is >1.5, repeat on the morning of surgery. Recommence therapeutic enoxaparin 12-24 h postoperatively, depending on the bleeding risk, and continue until warfarin has been recommenced, and the INR is within the therapeutic range.
Intermediate risk factors present
Cease warfarin five days preoperatively. Commence enoxaparin 40 mg/day four days preoperatively. This can be performed as an outpatient. Ensure that there is a minimum 12 h interval between last enoxaparin dose and surgery. Measure the INR the day before surgery. If the INR is >1.5, repeat on the morning of surgery. Recommence enoxaparin 40 mg/day 12 to 24 h postoperatively, and continue until warfarin has been recommenced, and the INR is within the therapeutic range.
No other risk factors present
Cease warfarin five days preoperatively. Commence enoxaparin 20 mg/day four days preoperatively. This can be performed as an outpatient. Ensure that there is a minimum 12 h interval between last enoxaparin dose and surgery. Measure the INR the day before surgery. If the INR is >1.5, repeat on the morning of surgery. Recommence enoxaparin 20 mg/day 12-24 h postoperatively and continue until warfarin has been recommenced and the INR is within the therapeutic range.
Using these guidelines, flowcharts for the preoperative management of anticoagulated patients can be constructed (Figures 1-3 ).
PREOPERATIVE HOME THERAPY
A standardized protocol for the management of anticoagulated patients should be readily available in the PAC. Patients not requiring inpatient management should be assessed for suitability for outpatient management. They must be capable of selfadministering LMWH subcutaneously, or be accessible to domiciliary nursing services. Although well motivated patients are capable of self administering LMWHs, a "hospital-in-the-home" program or its equivalent (e.g., family practitioner) is of benefit in supporting perioperative anticoagulation on an outpatient basis. Many patients are uncomfortable administering their own injections and are appreciative of nursing support. Others are not able to self administer parenteral drugs reliably, and require supervision, particularly if higher doses of enoxaparin are used.
Once the decision is made to manage anticoagulation as an outpatient, a prescription for the appropriate doses of LMWH should be provided. Pre-filled syringes should be supplied to the patient on prescription for storage in their home refrigerator, along with written instructions on when to cease warfarin therapy.
A mechanism for ensuring measurement of the INR on the day prior to surgery is required. In our institution, a blood sample is collected the day prior to surgery either by the domiciliary nurse (who returns the sample to the hospital laboratory), or by referring the patient to their local pathology service. Results should be available the night before planned surgery. Patients with an INR >1.5 have a repeat sample taken on arrival in the admitting unit on the day of surgery, and their surgery is scheduled to allow sufficient time to obtain a result preoperatively.
IMPLICATIONS FOR ANAESTHESIA AND SURGERY
These issues have been discussed extensively elsewhere 19, 35, 36, [45] [46] [47] [48] , so only a summary will be provided here. If the INR is >1.5 on the day of surgery, the alternatives include accepting a higher level of risk and performing the surgery as planned, modifying the technique to reduce the risk of bleeding, correcting the INR preoperatively by using fresh frozen plasma, or postponing the surgery 45 . The decision should be based not only on the absolute level of the INR, but also on the concurrent use of other anticoagulants or antiplatelet drugs 47 . There is no unequivocal data about what is a safe INR level for the performance of central neural blockade (CNB), because there is a baseline incidence of epidural haematoma, even in the absence of impaired coagulation 48 . In the authors' institution an INR of <1.3 is accepted as 'safe' and CNB is avoided if the INR is >1.5. If the INR is 1.3-1.5, other factors are taken into account, such as concurrent heparin therapy or antiplatelet medication, and each case is assessed on its merits.
All patients who have received LMWH within the previous 12 h can be assumed to have abnormal coagulation 19, 36, 48 levels may not always be helpful 36 . Therefore, CNB (needle or catheter insertion or removal) should not be performed within 12 h of administration (before or after) of a "prophylactic" dose of LMWH (enoxaparin 20 to 40 mg/day) or within 24 h of a "therapeutic" dose of LMWH (enoxaparin >1 mg/kg/day). These guidelines dictate that the last dose of homeadministered LMWH is given outside these time intervals.
In some patients there may be compelling clinical reasons for using CNB despite some degree of resi-dual anticoagulation. In these patients clinical judgement should be used to assess each case on its merits. In borderline cases, it may be safer to use a singleshot spinal block rather than a continuous epidural block. If a continuous epidural is indicated, high doses of local anaesthetic should be avoided, in order to facilitate neurological monitoring postoperatively. In all cases, postoperative neurological monitoring is mandatory, well after removal of the epidural catheter 36 .
In addition, mechanical methods for reduction of 
RESTARTING ANTICOAGULATION POSTOPERATIVELY
The issues related to restarting anticoagulation postoperatively are similar whether nor not patients are managed as outpatients preoperatively, and will not be discussed in detail in this paper. The principle that the risks of perioperative thromboembolism must be balanced against the risks of increased bleeding still applies. Generally, those patients at high risk for thromboembolism postoperatively (e.g., thromboembolism within previous 30 days) should be commenced on full anticoagulation (either IV UH or therapeutic LMWH) at the earliest opportunity, once the main risk of perioperative bleeding is over 13 . For patients at intermediate or low risk of thromboembolism, enoxaparin 40 mg/day or 20 mg/day respectively, should be recommenced 12 to 24 h postoperatively. In patients with a low risk of thromboembolism, but a high risk of bleeding, it may be reasonable to recommence oral warfarin at the preoperative dose without additional heparin cover. In any event, timing of restarting anticoagulation should be planned prior to discharge from the postanaesthesia care unit.
PERIOPERATIVE ANTICOAGULATION INFORMATION SHEET
Effective communication between the involved parties is important for all patients receiving anticoagulation, but particularly so for patients having their anticoagulation altered on an outpatient basis. For this reason, the introduction of a standardized "Perioperative Anticoagulation Information Sheet" for chronically anticoagulated patients presenting for surgery is recommended. Key features that should be identified are listed below. AUTHORS' EXPERIENCE In the authors' institution, these guidelines have been applied successfully to over 400 patients receiving chronic anticoagulation over the last two years. This represents approximately 3.0% of all elective surgical patients over this period. Initiation of the recommended management plan has improved the efficiency of the elective surgical service and has produced economic benefits with respect to reducing inpatient bed occupancy. No anaesthetic or surgical complications related to the preoperative outpatient management have been encountered. Clinical care has been facilitated by improved interdisciplinary communication and planning. In practice, the guidelines are most effective in patients with disease confined to a single system. Complex patients with multisystem disease often require a more individualized plan for management of their perioperative coagulation.
